RecruitingColorectal CancerSarcopenia

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Eligible age

60+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Sponsor: Wake Forest University Health Sciences

You may qualify if…

✓ Newly diagnosed metastatic CRC or newly recognized metastatic recurrence of CRC \>= to 3 months (12 weeks) from completion of treatment of non-metastatic CRC.
✓ Planning to or recently started to undergo undergo immunotherapy and/or 5-FU based chemotherapy as a first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan +/- immunotherapy. Capecitabine is also acceptable.
✓ Estimated life expectancy \>= 6 months.
✓ Patients must be able to comprehend English or Spanish (for questionnaire completion).
✓ Ability to understand and the willingness to sign a written informed consent document.
✓ Patient eligibility is not dependent on BMI or weight. Patients with a significant (+- \> 10%) body weight change in the previous 12 months are eligible for this study.

You may not qualify if…

✕ Patients enrolled on hospice.
✕ Prior systemic chemotherapy for metastatic colorectal cancer (ok if adjuvant chemotherapy completed \>= 3 months (12 weeks) prior to this disease disease recurrence and treatment).
✕ Patients may not be receiving any other investigational agents.
✕ No untreated brain metastases. Patients with treated brain metastases are eligible.
✕ Patients on or planned to undergo radiation therapy in near future.